Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04861584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Oct 3, 2026 → Oct 3, 2027
See other at-risk trials from Zhujiang Hospital

Record History

  1. Primary completion pushed from Oct 3, 2026 to Oct 3, 2027 Completion pushed from Apr 3, 2027 to Apr 3, 2028 · Eligibility criteria expanded, about 23 words · Secondary endpoints: details revised at 2 of 3 entries Show 3 more changesShow less
    • Completion pushed from Apr 3, 2027 to Apr 3, 2028
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Primary completion date: Oct 3, 2023 to Oct 3, 2026 Completion date: Apr 3, 2025 to Apr 3, 2027v5 Show 1 more changeShow less
    • Completion date: Apr 3, 2025 to Apr 3, 2027
  3. Primary completion date: Oct 3, 2022 to Oct 3, 2023 Completion date: Apr 2023 to Apr 3, 2025v4 Show 1 more changeShow less
    • Completion date: Apr 2023 to Apr 3, 2025
  4. Primary completion date: Oct 3, 2021 to Oct 3, 2022v3
  5. Trial status: Not Yet Recruiting to Recruiting Primary endpoint revised · Study sites: 0 to 1 · Primary completion date: Aug 2021 to Oct 3, 2021 · 5 morev2 Show 8 more changesShow less
    • Primary endpoint revised
    • Study sites: 0 to 1
    • Primary completion date: Aug 2021 to Oct 3, 2021
    • Start date changed from estimate of Apr 2021 to Jun 3, 2021
    • Interventions: Neoadjuvant Teriprizumab in Combination With Gemcitabine and Cisplatin (Drug) to Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin (Drug)
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study description revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Zhujiang Hospital
72 trials monitored
See 5 trials at risk
Bladder Cancer
1,022 trials monitored
See 71 trials at risk
This is a pre-surgical study involving subjects with local advanced bladder cancer, who are candidates for neoadjuvant therapy. It is a single-arm phase II portion.
Trial Details
NCT Number NCT04861584
Lead Sponsor Zhujiang Hospital
Conditions Urinary Bladder Cancer
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov